In a recent study published in the journal eClinical Medicine, researchers performed a meta-analysis to evaluate the glucose-lowering potential of glucagon-like peptide-1 receptor agonist (GLP-1 RA)-based therapies among diabetes mellitus type 2 (T2D) patients. Novel GLP-1-RAs, including tirzepatide, individually or combined with insulin fixed-ratio combinations (FRCs) or sodium-glucose cotransporter-2 inhibitors…